Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a report issued on Wednesday,Benzinga reports. They currently have a $46.00 target price on the stock. BTIG Research’s price objective would indicate a potential upside of 68.44% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Truist Financial dropped their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Stock Performance

MAZE stock opened at $27.31 on Wednesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics has a 1 year low of $12.81 and a 1 year high of $53.65. The company has a market cap of $1.51 billion, a P/E ratio of -10.79 and a beta of 2.21. The stock’s fifty day moving average price is $27.63 and its 200-day moving average price is $33.32.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, equities analysts forecast that Maze Therapeutics will post -2.73 earnings per share for the current year.

Insider Buying and Selling at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at $717,675. The trade was a 22.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 14,609 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total value of $436,809.10. Following the transaction, the chief marketing officer owned 14,609 shares of the company’s stock, valued at approximately $436,809.10. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 141,470 shares of company stock valued at $3,902,714. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

Large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its stake in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Maze Therapeutics in the 4th quarter worth $39,000. Ameritas Investment Partners Inc. increased its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the fourth quarter valued at about $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics in the second quarter valued at about $48,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.